NCT04291456 (MS) is a Phase 3 clinical trial of Minocycline 100mg in Multiple Sclerosis, sponsored by University of Calgary.

Who is sponsoring NCT04291456?

NCT04291456 is sponsored by University of Calgary.

What drugs are being tested in NCT04291456?

Interventions in NCT04291456: Minocycline 100mg.

What condition does NCT04291456 study?

NCT04291456 studies Multiple Sclerosis, Clinically Isolated Syndrome.

Is NCT04291456 still recruiting?

NCT04291456 is currently terminated. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT04291456: MS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minocycline in MS: Confirmation of Benefit

Terminated Phase 3 Last updated 24 March 2023

What this trial tests

Phase 3 trial testing Minocycline 100mg in Multiple Sclerosis in 9 participants. Terminated before completion.

Timeline

31 January 2020

Primary endpoint
16 December 2022

31 December 2022

Quick facts

Lead sponsor	University of Calgary
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	31 January 2020
Primary completion	16 December 2022
Estimated completion	31 December 2022
Sites	1 location across Canada

Drugs / interventions tested

Minocycline 100mg — full drug profile →

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Clinically Isolated Syndrome — all drugs for Clinically Isolated Syndrome →

Sponsor

University of Calgary

Who can join

Adults 18 to 60, any sex, with Multiple Sclerosis or Clinically Isolated Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm in diameter, and at least one of which is ovoid or periventricular or infra-tentorial. Treatment with minocycline until the endpoint is reached or to a maximum of 24 months or until the last-enrolled participant reaches their 12 month visit.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the gut to treat multiple sclerosis.
Ghezzi L, Cantoni C, Pinget GV, Zhou Y, et al · · 2021 · cited 84× · PMID 34196310 · DOI 10.1172/jci143774
Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
Mallah K, Couch C, Borucki DM, Toutonji A, et al · · 2020 · cited 70× · PMID 33013859 · DOI 10.3389/fimmu.2020.02021
Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines.
Park CS, Kim SH, Lee CK. · · 2020 · cited 25× · PMID 33425432 · DOI 10.4110/in.2020.20.e47
Current and Future Immunotherapies for Multiple Sclerosis.
Bourque J, Hawiger D. · · 2021 · cited 13× · PMID 34373668
From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment.
Raghib MF, Bernitsas E. · · 2023 · cited 4× · PMID 38002068 · DOI 10.3390/biomedicines11113069

Verify or expand the search:

Other trials of Minocycline 100mg

Trials testing the same drug.

NCT07082855 — A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigment · Phase 3 · not yet recruiting
NCT01755611 — Bioequivalence Minocycline Bioequivalence · Phase 1 · completed

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other University of Calgary trials

Trials by the same sponsor.

NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04291456 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Calgary
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04291456.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing